

# A trial comparing conventional fractionation with 'CHART' in the treatment of head and neck cancer

<b>Submission date</b> 28/02/2001	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 28/02/2001	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 29/10/2019	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr James Lyddiard

**Contact details**  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA  
-  
abc@email.com

## Additional identifiers

**Protocol serial number**  
CH02

## Study information

**Scientific Title**

A trial comparing conventional fractionation with 'CHART' in the treatment of head and neck cancer

**Study objectives**

To compare the effectiveness of radical fractionated radiotherapy given daily over 6 weeks with CHART over 12 days, with respect to local tumour control, survival and morbidity

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Cancer

**Interventions**

Conventional radiotherapy arm - 2 Gy, once daily five days a week over six weeks (large volume - 44 Gy in 22 fractions followed by small volume - 16 Gy in eight fractions)

CHART arm - 1.5 Gy, three time daily over 12 treatment days (large volume - 37.5 Gy in 25 fractions followed by small volume - 16.5 Gy in 11 fractions)

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

1. Local tumour control
2. Survival
3. Morbidity

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

01/03/1995

# Eligibility

## Key inclusion criteria

1. Histologically proven squamous cell carcinoma of all grades at one of the following sites: Nasal sinuses, Nasopharynx, Oral cavity, Oropharynx, Hypopharynx, Carcinoma of the larynx
2. A radical course of external beam radiotherapy is the appropriate sole treatment

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Not Specified

## Sex

Not Specified

## Key exclusion criteria

There should be no evidence of distant metastases beyond the regional nodes in the neck

## Date of first enrolment

01/01/1990

## Date of final enrolment

01/03/1995

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

# Sponsor information

## Organisation

Medical Research Council (MRC) (UK)

# Funder(s)

## Funder type

Research council

## Funder Name

Medical Research Council (MRC) (UK)

## Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration